Clinical Trial

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Study acronym: BRESELIBET
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-05-05; most recent amendment 2024-02-23.
Status change: Not Yet Recruiting → Recruiting 2020-11-28
Trial Details
NCT Number NCT04378647
Lead Sponsor Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Conditions Hodgkin Lymphoma, Adult
Enrollment 150 participants
Start Date 2020-06-01
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-26